Pacira BioSciences, Inc. (PCRX) Stock Analysis
Momentum Cont setup
Healthcare · Drug Manufacturers - Specialty & Generic
Hold if already holding. Not a fresh buy at $25.52, but acceptable to hold if already in. Reasons: Target reached (-2.1% upside); Market cap $0.99B below $1B minimum.
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable... Read more
Hold if already holding. Not a fresh buy at $25.52, but acceptable to hold if already in. Reasons: Target reached (-2.1% upside); Market cap $0.99B below $1B minimum. Chart setup: Trend continuation, RSI 64, MACD bullish. Market cap $0.99B below $1B minimum. Not in investable universe. Score 4.6/10, moderate confidence.
Passes 4/8 gates (clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on weak momentum and favorable risk/reward ratio and death cross (50MA < 200MA) and earnings proximity 0d<=7d. Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
3 floor-breakers
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $25.52, but acceptable to hold if already in. Reasons: Target reached (-2.1% upside); Market cap $0.99B below $1B minimum. Chart setup: Trend continuation, RSI 64, MACD bullish. Market cap $0.99B below $1B minimum. Not in investable universe. Target $25.62 (+0.4%), stop $23.79 (−7.3%), A.R:R -0.1:1. Score 4.6/10, moderate confidence.
Take-profit target: $25.62 (+0.4% upside). Target $25.62 (+0.4%), stop $23.79 (−7.3%), A.R:R -0.1:1. Stop-loss: $23.79.
Target reached (-2.1% upside); Market cap $0.99B below $1B minimum.
Pacira BioSciences, Inc. trades at a P/E of 157.1 (forward 7.2). TrendMatrix value score: 6.8/10. Verdict: Hold.
13 analysts cover PCRX with a consensus score of 3.8/5. Average price target: $29.
What does Pacira BioSciences, Inc. do?Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain...
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature to targeted nerves to produce neurolytic block that interrupts the pain-transmitting signals of a peripheral nerve. It also develops PCRX-201, a novel gene therapy vector platform enabling local administration of genetic medicines with the potential to treat large prevalent diseases like osteoarthritis. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product for use in animals. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Brisbane, California.